METHODS: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients.
RESULTS: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype.
CONCLUSIONS: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.
方法:本意大利多中心回顾性研究涉及晚期BRAF突变型NSCLC。评估BRAFV600E和非V600E患者的完整临床病理数据。
结果:共纳入44例BRAFmutNSCLC患者(V600E,n=23;非V600E,n=21)。生存结果和治疗反应无显著差异,根据V600Evs.非V600E突变,尽管在V600E亚组中观察到了延长PFS的趋势(中位PFS=11.3vs.非V600E的6.0个月)。在总人口中,ECOGPS和年龄对操作系统有显著影响,而骨病变与较短的PFS有关。与免疫疗法相比,一线化疗与总体人群的OS延长相关,尤其是在BRAFV600E亚型中。
结论:这里,我们报告了有BRAF改变的晚期NSCLC回顾性队列的真实数据.我们的研究提供了生存结果的相关线索,治疗反应,与BRAF突变型NSCLC的临床病理相关性。